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Background: Myocardial infarction is the leading cause of death worldwide. Stroke is the 
third most common cause of death in the western world, and the primary cause of permanent 
disability. Both diseases are, in the majority of the cases, a result of atherosclerotic plaque 
formation and rupture. Many common risk factors and preventive options have already been 
discovered for these diseases, but the incidence remains high.  
Red cell distribution width (RDW) is a measure of the variability in size of the circulating 
erythrocytes. It is calculated by most common blood cell counters. Over the last few years it 
has been associated with a specter of disease entities including arterial cardiovascular disease. 
The underlying reason for the observed associations remain unknown.  
Aim: The aim of this literature study is to give an overview of the epidemiology and 
pathophysiology of atherosclerosis, ischemic heart disease and stroke, and present the 
available literature on the relationship between RDW these diseases. Lastly, potential 
underlying mechanism for the observed associations will be discussed.  
Method: I’ve approached the problem by use of scientific literature both published as books 
and relevant research articles. I collected the research articles from the MEDLINE database 
by using the medical search engines PubMed and Google Scholar.   
Results: Many low-scale retrospective and some larger prospective studies have described 
relationships between RDW and myocardial infarction, stroke and atherosclerosis. There are 
also a few studies reporting the contrary. RDW has also been described as a prognostic 
marker for mortality after myocardial infarction.  
Conclusion: RDW is related to atherosclerosis, myocardial infarction and stroke, and can 
potentially be used as a novel biomarker for risk stratification and prevention of disease. The 
underlying mechanism for the associations remains unknown, but in most of the literature 
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Cardiovascular disease (CVD) is a collective term including all heart and blood vessel 
diseases. Diseases related to the process of atherosclerosis, like heart attack, stroke and 
peripheral arterial disease, are all included in the term, as well as disease entities like 
arrhythmias, heart valve problems and venous thrombosis. In this literature study, my focus is 
going to be on arterial cardiovascular diseases including ischemic heart disease, stroke and 
atherosclerosis.  
Atherosclerosis, the process of development and rupture of atherosclerotic plaques, is 
the leading cause of myocardial infarction, ischemic stroke and peripheral artery disease (1-
3). Ischemic heart disease due to atherosclerosis is the leading cause of death both worldwide 
and in Europe. It is estimated that CVD is responsible for over four million deaths yearly in 
Europe, which makes it attributable for about 51% of deaths in women, and 42% of deaths in 
men (4, 5). Many of the deaths due to CVD happens prematurely (<75 years), and the 
disease(s) accounts for 37% of all premature deaths in Europe. Over the last few decades the 
evolution of treatment and prevention of acute myocardial infarctions have markedly 
decreased disease mortality rates. Incidences, on the other hand, are more stable and even 
increasing among women in some populations (6). However, recent results from the same 
Norwegian population show that the incidence rates are decreasing as well (7). 
Cerebrovascular events, more commonly known as strokes, are the number one cause of 
permanent disability, and the third most common cause of death in the western world (8-10) 
Atherosclerosis plays a significant role in cerebrovascular events, especially the ischemic 
strokes (11). In addition to the arterial cardiovascular diseases, the CVD term includes 
arrhythmias, heart valve diseases, congenital heart disease, deep vein thrombosis, pulmonary 
embolism and rheumatic heart disease. These disease entities will not be discussed in this 
thesis.  
Cardiovascular disease is without doubt an important public health problem, with 
ischemic heart disease and stroke on top of WHOs cause of death statistics (12). Prevention 
and early intervention is crucial to decrease these numbers. Except for genetic predisposition, 
gender and age, many of the commonly known risk factors for cardiovascular diseases are 
modifiable. Such risk factors include smoking, physical activity, alcohol consumption, diet, 
overweight, hyperglycemia, hyperlipidemia and hypertension (13-24). These can be 
controlled and treated with medication and/or by alteration of life-style. Identification of new 
risk factors is also an important step in the prevention of CVD. Biomarkers able to predict 
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cardiovascular outcomes can aid identification of subjects in need for early intervention, and 
thereby prevent fatal events. One such biomarker is Red blood cell Distribution Width 
(RDW), which is a measure of the variability in size of the circulation erythrocytes. Over the 
last few years, the association between RDW and various disease outcomes has been studied 
broadly. Especially the association between RDW and cardiovascular diseases is described in 
detail. However, little is known with regard to the underlying mechanism for this observed 
relationship. 
In this literature study, I will first give a comprehensive overview of the epidemiology 
and pathophysiology of atherosclerosis, ischemic heart disease and stroke, as well as their 
common risk factors. Afterwards I am going to present available publications on RDW and 





Red Cell Distribution Width (RDW) 
 
Measurement 
Red cell distribution width is a measure of the variability in size of the circulation 
erythrocytes and could be looked at as the electronic equivalent to the anisocytosis judged 
from a peripheral blood smear. It gives the coefficient of variation of the red blood cell 
volume in percentage, and thereby expresses the width of the volume curve. At the University 
Hospital of North Norway, the reference range for RDW is 11.7-14.5. It is calculated by 
dividing the standard deviation (SD) of the mean corpuscular volume (MCV) by the MCV, 
and multiplying by 100 to yield a percentage value (figure 1).  
 
𝑹𝑫𝑾 (%) =  
𝑺𝑫 𝒐𝒇 𝑴𝑪𝑽
𝑴𝑪𝑽 
 𝒙 𝟏𝟎𝟎 
(Figure 1) 
 
Most automated blood cell counters calculate this value in a normal blood cell count. This 
makes it widely available and relatively inexpensive.  
 
What causes a change in RDW? 
RDW values vary with diseases that alter the erythropoiesis and the composition of red blood 
cells. For instance, a condition that increases the release of immature red blood cells from the 
bone marrow will cause an increase in RDW because the immature cells are larger in volume 
than the mature cells and thereby leads to a greater span of the volume distribution curve. 
Hemoglobinopathies, like sickle-cell disease, and other hematological diseases may also 
cause an increase in RDW (25-27). Traditionally, the measure is used in the differential 
diagnosis of anemia. Because RDW becomes elevated earlier than other blood parameters, it 
is also helpful for early diagnosis of nutritional deficiency (28). Folic acid and B12 
deficiencies will often present with high values of both MCV and RDW, while an iron 
deficiency anemia is characterized by a high RDW and low MCV. If blood cells are 
fragmented, agglutinated or dimorphic, this may also cause an elevation in RDW, and blood 





Over the last years, RDW has been associated with a vast number of diseases and both 
cause specific and overall mortality. Associations include conditions affecting almost all parts 
of the body. The specter is wide, and elevated RDW is associated with outcomes that stretches 
from mortality in acute pancreatitis (29), mortality in trauma patients (30), risk of dementia 
(31), mortality in patients with septic shock (32), to an unfavorable lipid profile (33). RDW is 
also associated to increased HbA1c levels (34), subclinical hypothyroidism (35), mortality in 
critically ill patients (36), mortality and morbidity in patients with community acquired 
pneumonia (37), and mortality in patients with chronic obstructive pulmonary disease (38). 
Lastly, RDW has been described in relation to non-alcoholic fatty liver disease (39), mortality 
in kidney transplant recipients (40), venous thromboembolism (41), and atrial fibrillation (42). 
The relation to arterial cardiovascular diseases has also been described in an increasing 
fashion over the last few years. A more detailed description of these are found under the 
section on the relation between RDW and CVD. The association to such a wide span of 
diseases and outcomes has obviously led to questions about the underlying mechanisms for 
the observed relationships. One thought is that RDW might just be a marker of poor health, 
and reflects an inflammatory process going on in the body. Inflammatory cytokines are 
known to influence the bone marrow and erythropoietin, and thereby alter the composition of 
red cells which leads to a change in RDW. Many studies support this theory. A study 
including 3845 adult outpatients demonstrated a graded association between quartiles of 
RDW and high-sensitivity CRP and erythrocyte sedimentation rate. This relationship was 
independent of hemoglobin levels, MCV, age, sex and ferritin, and was thereby not due to the 
subjects being anemic (43). The association between RDW and CRP is also described in 
different selected populations, including overweight adolescents (44), subjects with 
hypertension (45), and in patients with Alzheimer’s disease (46). In 195 patients with systolic 
heart failure, RDW was found to be associated with an increase in soluble tumor necrosis 
factor (TNF) receptor I and II. In the same study, multiple correlations were found between 
RDW and interleukin-6 and C-reactive protein (47). In 144 subjects with adult congenital 
heart disease, RDW was significantly associated with raised IL-6 levels (48). In patients with 
non-alcoholic steatohepatitis, RDW was found to be a sensitive and specific method for the 
assessment of inflammation (49). 
A study from 1995 describes the variation in different blood cell parameters 
throughout a year on an individual level (50). The study included 26 participant which had an 





During a day, the bone marrow of a healthy human produces no less than 1012 red blood cells 
through the process called erythropoiesis. Through formation and maturation of red blood 
cells, the cells go through several phases in which they have different shapes, sizes and names 
(51).  
It all begins with the stem cell. This passes through the progenitor cells BFUE (burst-
forming unit erythroid) and CFUGEMM (colony forming unit granulocyte, erythroid, monocyte 
and megakaryocyte) to the first erythrocyte precursor that resembles a red blood cell in the 
bone marrow, namely the pronormoblast. The pronormoblast, a large cell, goes through 
several cell divisions to form gradually smaller normoblasts. The cells get smaller, but contain 
an increasing amount of haemoglobin. The nucleus is eventually squeezed out of the cell, 
leaving behind some ribosomal RNA which makes it capable of haemoglobin synthesis. The 
cell is now called a reticulocyte, and is larger than a mature red blood cell. The reticulocyte 
stays for about 1-2 days in the bone marrow before entering the blood stream. It circulates for 
1-2 days losing the rest of its RNA, and shrinking further in size to become a mature 
erythrocyte. One pronormoblast usually gives rise to 16 mature red blood cells (figure 2) (52).  
 




Either it’s through hemolysis, bleeding, anemia or some other condition causing a hypoxic 
state, the body will respond by producing/releasing erythropoietin (EPO). Normally, about 
90% is synthesized in peritubular interstitial cells of the kidneys, and 10% is made in the 
liver. The hormone is produced in response to oxygen tension in the kidneys. Hypoxia leads 
toincreased EPO production. EPO is considered the principle regulator of red blood cell 
production (53). It is crucial for the final step in maturation erythroid cells (54).  EPO 
stimulates many steps in the maturation from stem cell to erythrocyte, including the late 
BFUE, the CFUE, the pronormoblasts and the normoblasts.  
The erythropoiesis is an important topic in understanding why the RDW differs both 
intra- and inter-individually. Everything affecting the synthesis or function of EPO will have 
some sort of impact on RDW. So will other factors affecting the erythropoiesis. The RDW 
measures the variation in size of the circulating red blood cells, but does not differentiate 
between mature erythrocytes and reticulocytes. Thereby, an increased release of reticulocytes 
will lead to an increased RDW due to the reticulocytes being larger in size than the mature 
erythrocytes. A reduced release of reticulocytes will have the opposite effect, by increasing 
the proportion of evenly-sized mature cells. All factors affecting the erythropoiesis, through 








Atherosclerosis is the principal cause of heart attack, stroke and gangrene of the extremities 
(2), and is thereby the underlying disease responsible for some of the leading causes of death 
world-wide. A study of asymptomatic atherosclerosis in 526 subjects aged 45-84 showed a 
prevalence increasing rapidly with age. Between 55-64 years of age, 2.4% of males had 
carotid artery stenosis of any grade. In males aged 75-84, the prevalence increased to 30.3% 
for stenosis <50% of the lumen, and to 6,1% for stenosis greater than 50% of the lumen. 
Minimal lesions (< 15%) were very prevalent even at relatively young ages, with 32.1% in 
males 45-54 years (55). In a study of Finnish men aged 42, 48, 54 and 60 years, only 51% 
were free of any detectable carotid atherosclerosis. The prevalence in the four age groups 
were 14.1%, 32.0%, 67.7% and 81.9% respectively (56). Studies show that atherosclerosis 
starts early. In 262 transplanted hearts with a mean age of 33.2 years, lesions were present in 
1 out of 6 (57). For all studies discussed, the prevalence tended to be higher among men than 
women. In a study of 3016 men and 3404 women aged 25-84 years, both plaque prevalence 
and morphology differed between the genders. Atherosclerotic plaques were found in 55.4% 
of men and 45.8% of women. The plaque prevalence was similar in men and women at older 
ages, with the “turning point” of male predominance at around 50 years suggesting a 
menopausal effect on the prevalence in women. The men had a higher rate of soft, echolucent 
plaques than women, maybe explaining why acute coronary events are more common in older 
men even though the prevalence of atherosclerosis is more or less the same (58).  
The hard end points of atherosclerosis in the coronary and carotid arteries, myocardial 
infarction and stroke, are well known. However, atherosclerosis might cause serious damage 
all around the body, with potentially critical outcomes. A study exploring renal artery 
stenosis, an important cause of hypertension and kidney failure, showed that subjects with 
atherosclerosis elsewhere had a high prevalence of significant renal artery stenosis (59). 
Peripheral arterial disease (PAD) increases markedly with age. Atherosclerosis in peripheral 
arteries can lead to claudication and gangrene if they get totally occluded With PAD defined 
as ankle-brachial index of less than 0.95, the frequency of intermittent claudication increased 
from 0.6% in subjects 45-54 years, to 2.5% in those aged 55-64 years, and was 8.8% among 




Through a process called atherogenesis, atherosclerosis is formed in the tunica intima zone of 
the arterial vessel walls (Figure 3), primarily the large and medium-sized elastic and muscular 
arteries (3). Normally, this is a very slowly developing lesion that might take decades to 
become clinically significant. The “atherosclerotic plaques” protrude into the vessel lumen 
and obstructs the blood flow. This obstruction is dangerous in itself, but the atherosclerotic 
plaques also weakens the underlying tunica media which may lead to plaque rupture and the 
creation of an acute arterial thrombosis (61). Such plaque ruptures cause acute myocardial 
infarctions and strokes.  
 
Figure 3, Microscopic anatomy of the artery, Blausen.com staff. "Blausen gallery 2014" 
  
Due to the very important role of atherosclerosis in the most deadly diseases in the Western 
world, it is heavily studied. The current view of the pathogenesis of the disease supports a 
model that regards atherosclerosis as an inflammatory disease – a chronic inflammatory 
response from the arterial wall due to endothelial injury (62). The endothelial injury arises 
from a combination of many different factors. After the primary injury to the vessel wall, the 
lesion progresses through interactions of modified lipoproteins, monocyte-derived 
macrophages, T lymphocytes and the normal cellular constituents of the arterial wall, like 
smooth muscle cells (61). The process of atherogenesis often starts at an early stage in life. 
Fatty streaks, the earliest type of lesion in the atherogenesis, consist only of monocyte-derived 
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macrophages and T lymphocytes. Such fatty streaks are common in infants and young 
children (63). Step by step the atherogenesis can be described like this: 
1. Chronic endothelial injury due to a combination of different factors including (but not 
limited to) hyperlipidemia, hypertension, smoking, homocysteine, hemodynamic 
factors, toxins, viruses and immune reactions.  
a. The hemodynamic turbulence play an important role in endothelial cell injury, 
shown by the fact that atherosclerotic plaques tend to form at points where 
vessels branch out, at ostia of exiting vessels and on the posterior wall of the 
abdominal aorta, where there are disturbed flow patterns.  
b. The blood pressure plays an important role in weakening the vessel wall. A 
good example of this is the big difference between the systemic and the 
pulmonary circulation when it comes to atherosclerosis. The pulmonary artery 
has a blood pressure far lower than the rest of the body, with an average of 
about 25/8 mmHg. Partly because of this, atherosclerosis is almost completely 
absent in the pulmonary circulation (64, 65).  
c. Another important contributor is the hyperlipidemia. It may increase local 
production of reactive oxygen species leading to accelerated nitric oxide decay, 
which is important for vasodilatation. This increases the local shear stress on 
the vessel wall.  
d. Inflammation is also important for injury to the vessel wall. As soon as 
endothelial cells become dysfunctional, they start expressing adhesion 
molecules that contribute to leukocyte adhesion. Primarily monocytes and 
CD4+ T-lymphocytes, but also natural killer T-cells in early lesions. Vascular-
cell adhesion molecule 1 (VCAM-1) is typically upregulated in response to 
hypercholesterolemia, and because monocytes and T-lymphocytes carry the 
counterreceptors for VCAM-1, these are the blood cells that primarily adhere 
(66). However, all blood cells passing along the surface of the blood vessel 
might adhere to the activated endothelium.  
2. The injury to the endothelium causes a chronic endothelial dysfunction leading to 
increased permeability, leukocyte adhesion and emigration. Chemokines in the intima 
stimulate the blood cells to migrate through the junctions between the endothelial 
cells, and thereby allows them to pass into the subendothelial space. In the tunica 
intima, monocytes transform into macrophages and starts eating up lipoproteins like 
oxidized LDL. This leads to the formation of so-called foam cells. The macrophage 
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activation leads to cytokine production and further leukocyte adhesions and 
inflammatory cell recruitment. Cytokines released from the T-cells leads to increased 
activity in the cytokine cascade and increased production of interleukin-6 and C-
reactive protein. Thus, the local inflammatory process of the atherosclerotic lesions 
leads to a systemic activation. T-lymphocytes in the intima interact with macrophages 
and generate the chronic inflammatory state (67, 68). At this point the lesion is called 
a “fatty streak”, with primarily intracellular lipids. The activated leukocytes in the 
atherosclerotic lesion release growth factors that stimulate smooth muscle cell 
proliferation and synthesis of extracellular matrix. These fatty streaks are prevalent in 
young people and they never cause symptoms. In some they progress to 
atherosclerotic plaques, and in some they disappear (69) (Figure 4).   
3. Proliferation of smooth muscle cells and deposition of extracellular matrix (collagen) 
converts the fatty streak into a fully developed atherosclerotic plaque. The center of 
the atheroma consists of foam cells (macrophages rich on lipids) and extracellular 
lipid droplets. Around this core there is a cap of smooth muscle cells, and a collagen-
rich matrix. Such plaques are relatively stable, but the inflammatory cells in the plaque 
may produce inflammatory molecules and proteolytic enzymes that induce smooth 
muscle cell apoptosis and catabolism of the extracellular matrix, which weakens the 
fibrous cap of the plaque and leads to plaque instability (70). 
Figure 4, Progression of atherosclerotic plaques, Robbins basic pathology 8th edition  
 
Studies show a relationship between atherosclerosis and increased blood plasma levels of 
inflammatory biomarkers (71-73). Many of the same biomarkers, especially CRP, are 
associated with angina pectoris, and an increased risk of arterial thrombotic events (74-77). 
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This relationship is most likely mediated through the ongoing chronic inflammatory process, 
the atherosclerosis, which precedes the vast majority of these atherothrombotic events.  
 
Ischemic Heart Disease 
Ischemic heart disease is a collective term for a group of related syndromes that result from 
myocardial ischemia. Ischemia occurs when the oxygen demand of the heart muscle, 
myocardium, is greater than the supply. A situation like this is most often a result of 
narrowing of the coronary arteries due to atherosclerosis.  
Ischemic heart disease presents in its mildest form as angina pectoris. Directly 
translating to “chest pain”, angina pectoris is painful but does not lead to cell death and 
necrosis of the myocardium. Stable angina pectoris occurs at different levels of exhaustion 
when the heart rate increases and the oxygen demand becomes too high, for instance during 
exercise or stressful situations. In the case of stable angina, the pain will disappear after a 
short while if the person comes to rest. The angina is referred to as unstable if the symptoms 
occur at progressively less exertion or at rest.  
 
Epidemiology 
Ischemic heart disease is the leading cause of death both worldwide and in Europe. It is 
estimated that cardiovascular disease is responsible for over four million deaths yearly in 
Europe, which makes it attributable for about 51% of deaths in women, and 42% of deaths in 
men (4, 5). Many of the deaths due to CVD happens prematurely (<75 years), and the 
disease(s) accounts for 37% of all premature deaths in Europe. According to an update from 
2010, the overall prevalence of myocardial infarction in the US population 20 years or older 
were 4.7% in men and 2.6% in women (78). The prevalence varies with race, especially for 
men, with a prevalence of 5.1% among non-Hispanic white men, 3.6% among non-Hispanic 
black men, and 2.6% among Mexican American men. The incidence of fatal and non-fatal 
myocardial infarctions among women “lagged” around 20 years behind the incidence of men. 
However, the age-adjusted prevalence of angina pectoris was higher among women than men. 
The update approximates that about 1 in 6 deaths in the US are caused by coronary heart 
disease. The incidence and prevalence differs markedly all around the world. In a country like 
Japan, which is economically comparable to the western world, the rate of coronary heart 
disease is only one fourth of the rate in North America. This suggests that both genetic 




Myocardial infarction occurs due to prevention of blood flow through the coronary arteries, 
and is the necrosis of heart muscle cells due to ischemia. A myocardial infarction may be 
fatal, but it can also be “silent” and go by totally undetected (80). Either by reducing oxygen 
demand, or by reperfusion through some intervention, the myocardial cells might survive. If 
not, coronary occlusion will lead to cell death within short time. Most of the myocardial 
infarctions are a result of coronary thrombosis following thrombus formation on the surface of 
an activated atherosclerotic plaque (81). These arterial thrombi consists of platelets, fibrin, 
erythrocytes and degenerating leukocytes. What causes an atherosclerotic plaque to rupture? 
All the components of the atheroma affect its stability in different ways. Destabilization 
happens through production of coagulation factors, radicals and vasoactive molecules by the 
macrophages and T-cells. These molecules inhibit the stable fibrous caps, attack the collagen 
stabilizing the caps, and initiate thrombus formation (69, 82, 83).  
In a typical myocardial infarction, the coronary artery occlusion follows the sequence 
below, as derived from Robbins Basic Pathology: 
- It all starts with a sudden break in the surface of an atherosclerotic plaque. This can 
happen through hemorrhage, ulceration, rupture, or for other reasons. The 
subendothelial collagen and necrotic plaque contents are exposed to the blood stream.  
- Platelets adhere to this disrupted plaque, aggregate, becomes activated, and release 
potent secondary aggregators including thromboxane A2, adenosine diphosphate and 
serotonin.  
- Vasospasms are stimulated by mediator release and 
platelet aggregation. 
- Other mediators activate the extrinsic pathway of the 
coagulation, adding to the bulk of the thrombus.  
- It all builds up, and within minutes, the thrombus can 
have grown so big it completely occludes the lumen of the 
coronary vessel. 
- The atherosclerosis have three main pathogenic events. 
Aneurysm, occlusion due to rupture of atherosclerotic plaque 
and thrombus formation, or stenosis due to growing plaque 
(figure 5).  
Figure 5, main pathogenic events of atherosclerosis, Robbins basic pathology 8th edition 
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When the coronary artery blood supply is blocked and the myocardium has to work 
anaerobically, lactic acid and other breakdown products start accumulating within seconds. 
Within a minute after onset of ischemia, the heart muscle loses its contractility. However, 
these changes to the functionality of the heart are reversible. Severe ischemia lasting 20-40 
minutes will on the other hand cause necrosis to the myocardium, and permanent damage to 
the contractile function. Five main factors will determine the size, location and lasting 
consequences of the myocardial infarction. Severity of the coronary occlusion, size of the area 
vascularized by the occluded artery, duration of the occlusion, demand by the myocardium, 
and the extent of collateral supply. With longer blockage than an hour, the microvascular 
system will also get damaged (61). The tissue with irreversible injury changes over the course 
of the days, weeks and months following the myocardial infarction. The necrosis following 
the ischemia – coagulation necrosis – ensues from around the fourth hour after the loss of 
blood supply and lasts for about three days. During the same period a neutrophilic cells starts 
infiltrating the tissue. From the third day, the breakdown of dead myofibers starts with some 
phagocytosis of dead cells by macrophages. Within the first week, phagocytosis of dead cells 
is at its peak, and some fibrovascular granulation tissue forms at the margins. Between day 10 
and 14, granulation tissue is abundant, with new blood vessels and deposition of collagen. The 
deposition of collagen continues up until about eight weeks after the myocardial infarction, 
and the cellularity decreases. The scarring process is now complete, and after two months, a 
dense collagenous scar is visible.  
Specific risk factors for myocardial infarction include factors that help cause the 
atherosclerotic plaque to rupture, and thereby start the whole process of thrombosis formation. 
The “architecture” of the plaque, the mechanical properties of the blood flow and vessel 
walls, and the biological composition of the extracellular matrix play a critical role in plaque 
stability (84). Studies have shown that there is poor correlation between which plaques that 
rupture and cause myocardial infarctions, and which plaque that are considered “severe” by 
angiography. In other words – angiography cannot detect the plaques that are vulnerable to 
rupture (85, 86).  This is because angiography says little about plaque structure and biological 
activity in the plaques core. Furthermore, clinical studies on lipid-lowering treatment show 
that these drugs lower the risk of cardiovascular events without any changes to the plaque 
severity as judged by angiography (87). The treatment works on the composition and activity 
of the plaque, rather than the size and progression.  
The walls and atheromas of the arteries undergo a mechanical stress that varies a lot 
with time. The mean arterial pressure is not constant, and the action of the heart causes a 
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pulsatile blood pressure leading to a repetitive dynamic impact on the vessel walls. These 
forces play an important role in plaque rupture, but are more or less the same throughout the 
arterial system. Which plaques that actually rupture is more dependent on the composition of 
the plaque core and the strength of the fibrous cap. The weaker the structure is, the less 
mechanical force (blood pressure) is needed to break it down. In mature atherosclerotic 
plaques, T lymphocytes and macrophages release proteolytic enzymes and cytokines that 
weaken the plaque and makes it more prone to rupture. Smooth muscle cells go into 
apoptosis, while the extracellular matrix is reduced through active degradation and decreased 
synthesis. The lipid core is also an important component in plaque stability. High levels of 
cholesterol does not only promote atherogenesis, but is also an important risk factor for 
rupture of plaques. As clinical trials with lipid-lowering drugs show decreased morbidity and 
mortality, it is likely to think that a healthier lipid profile changes the composition of the 






Stroke is a collective term for conditions that lead to an acute loss of blood supply leading to 
infarction of the brain tissue. This can happen through thrombotic or embolic occlusion of 
vessels, or rupture of vessels leading to hemorrhage. A global ischemia can also occur in 
situations with low cerebral perfusion pressure, caused by either a drop in mean arterial 
pressure, a raise in intracranial pressure, or a combination of the two.  
 
Epidemiology 
Cerebrovascular events are the number one cause of permanent disability, and the third most 
common cause of death in the western world (8-10). Strokes accounted for 1 in every 18 death 
in the US in 2006. Between ages 45-64 years, 8-12% of ischemic strokes and 37-38% of 
hemorrhagic strokes are fatal within 30 days (78). Studies show that up to 30% of stroke 
survivors are permanently disabled, and up to 20% require institutional care within 3 months 
after onset (88). Even though many survive a first stroke, the prognosis is bad. For patients 
more than 40 years of age, 47% of men and 51% of women will be dead within five years.  
Both Japanese and Chinese populations have higher rates of cerebrovascular events than 
coronary heart events, which is completely opposite from Western populations (79).  
 
Pathophysiology 
Most common are the ischemic strokes resulting from a thrombotic or embolic narrowing or 
occlusion of an artery leading to or within the brain. Contrary to the myocardial infarctions, 
the ischemic strokes are mostly due to embolic thrombi rather than in situ thrombus 
formation. Thus, for the majority of the events, the pathophysiological mechanisms leading to 
the occluded artery are different compared to myocardial infarctions. The emboli leading to 
focal cerebral ischemia arise from several different sources. As for myocardial infarction, 
atherosclerosis is the most common source of the thrombus, but for cerebral infarctions to 
occur the thrombus have to travel a stretch to cause its damage. The carotid bifurcation, the 
basilar artery and the origin of the middle cerebral artery are frequent sites for atherosclerotic 
plaque rupture that cause thromboembolism. The thrombus forming on ruptured plaques often 
fragment into smaller bits that travel with the blood stream and occlude smaller arteries where 
it is stuck. Ischemic strokes caused by atherosclerosis have essentially the same risk factors as 
myocardial infarctions (89). In addition to the thrombi caused by atherosclerosis, “mural 
thrombi” are also common in cerebral infarctions. These are thrombi occurring in the heart 
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chambers or in the aorta. Previous myocardial infarction, valvular disease, dilated 
cardiomyopathy, myocarditis, catheter trauma or atrial fibrillation are important factors 
predisposing for the generation of such mural thrombi (61). Thus, the ischemic strokes due to 
these mural thrombi have risk factors quite different from the ones previously described (90). 
The formation of the mural thrombi happens through adherence and aggregation of platelets 
when the subendothelium/subendocardium is exposed to the blood flow, either in one of the 
hearts chambers or in the aorta. Seconds to minutes after cerebral ischemia initiates, the 
“ischemic cascade” starts. Inadequate blood supply leads to anaerobic metabolism and the 
creation of lactic acid. Lactic acid disturbs the acid-base relationship in the brain cells, and 
can destroy them through a drop in pH. ATP-dependent ion transporters in the cell walls fail, 
and the membranes are depolarized. Subsequently, ions are “misplaced”, with a large calcium 
influx and potassium efflux. The excessive calcium entry activates proteases and lipases 
leading to breakdown of the cells’ membrane and the entry of harmful chemicals. The 
mitochondria break down, and apoptotic factors are released in the cell. Apoptosis starts and 
the necrotic cells release toxins harming other cells nearby (91).  
The hemorrhagic strokes account for about 13% of the stroke cases (92). Hemorrhages 
within the brain are caused by a variety of reasons. Hypertension or some other cause leading 
to vascular wall injury is common. Bleeds may also occur due to vascular malformations or 
brain tumors. Intraparenchymal hemorrhages are often due to the rupture of a small vessel 
caused by hypertension. Such bleeds typically occur in the basal ganglia, thalamus, pons and 
cerebellum (61). Subarachnoid hemorrhages, on the other hand, are caused by saccular 
aneurysms. Such rupture can occur at any time, but are associated with an acute increase in 






Risk factors for arterial cardiovascular disease 
With atherosclerosis being the principal cause of myocardial infarction and stroke, 
understandably there are many common risk factors for these diseases. Nonetheless, many of 
the common risk factors have different impact on the different disease outcomes. For instance, 
it is described that smoking has the largest impact on peripheral arterial disease leading to 
intermittent claudication, while cholesterol levels has the largest impact on coronary arteries, 
and blood pressure is the most important factor in cerebral atherosclerosis (64). 
Atherosclerosis is a multifactorial disease, and the majority of patients have more than one 
risk factor. It is also important to note that many of the risk factors interact with each other. 
For instance, blood sugar, cholesterol and hypertension can all be adjusted by changes in diet, 
physical activity and weight loss.  
 
Not modifiable 
The Framingham study shows that the risk of a coronary heart disease increases with age (93). 
The same study also shows a great difference in incidence between genders. In the study, 
every fifth man would suffer a coronary heart disease event by the age of 60, while the 
corresponding proportion is only one in every 17th for women. Family history of a premature 
coronary heart disease is a strong and independent risk factor for future MI. The risk ratio for 
MI for subjects with a family history of either parents was 1.61 in men and 1.85 in women 
(94). Another study showed that a family history of MI was predictive of all-cause and 
cardiovascular death in men, but not in women (95).  
 
Modifiable 
Most of the risk factors for cardiovascular outcomes are modifiable in one way or another, 
and changes might be achieved through medication and various life-style choices.   
Cholesterol has been a well-known risk factor for cardiovascular disease for a long 
time (21). The 4S study showed that treatment with cholesterol lowering simvastatin in 
patients with coronary heart disease had clear benefits with regard to both mortality and 
recurrent coronary events (22). Many similar trials have later shown the same (96-98). Both 
total cholesterol and LDL cholesterol levels can be used in prediction of CHD risk (99). 
Cholesterol is an important component of the atherosclerotic lesions as previously described, 
and high cholesterol levels increases the risk of atherosclerotic development and in turn the 
risk of myocardial infarction and stroke.  
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Hypertension plays a key role in both plaque formation and plaque rupture. Through 
constant pressure on the vessel wall, high blood pressure weakens the endothelium and 
thereby facilitates plaque formation. Likewise, high pressure on vulnerable plaques increases 
the risk of rupture (61). Hypertension is very common, increasing in prevalence with age 
(100), and an important contributor to cardiovascular morbidity and mortality (16, 101-103). 
Commonly, the goal of antihypertensive treatment has been systolic blood pressure<140 and 
diastolic blood pressure<90, and <130/<80 for some high risk groups (104, 105). Even in 
subjects with blood pressure below 140 systolic, there is a substantial potential for 
cardiovascular risk reduction through further lowering of the blood pressure. In a recent study, 
9351 persons were randomized to two different antihypertensive regimes, standard and 
intensive, with a goal of systolic blood pressure <140 and <120 respectively (106). The study 
was stopped prior to plan because of a significantly lower risk of morbidity and mortality in 
the intensive care group.  
Both microvascular and macrovascular changes occur in diabetes patients making 
them more susceptible to a wide range of diseases (107). Strong evidence links atherosclerotic 
cardiovascular disease with both type 1 and type 2 diabetes (15, 108-110). The vascular 
changes include endothelial cell dysfunction (111, 112) and vascular smooth muscle 
dysfunction (113). Individuals with diabetes also have altered more active platelet functions 
and abnormal coagulation through impaired fibrinolytic capacity (114-116). 
Smoking is another well-established easily (?) modifiable risk factor. All the way back 
in 1938 it was stated that cigarette smoking “impaired survivorship” (117). A summarizing 
article from 2004 states that cigarette smoking “impacts all phases of atherosclerosis from 
endothelial dysfunction to acute clinical events”. Cigarette smoking increases inflammation, 
thrombosis and oxidation of low-density lipoprotein (118). Numerous large epidemiological 
studies have confirmed the dangers of smoking (14, 119, 120). There is also an increased risk 
of death from ischemic heart disease among passive smokers. Nonsmokers living with 
smokers have a 30% increased risk of cardiovascular mortality (121).  
A large study conducted on youth in three European countries showed that low 
average activity level was associated with clustering of cardiovascular risk factors (122). 
Many studies have showed the same (19, 123, 124). Physical activity has a beneficial effect 
on many of the other cardiovascular risk factors, like hypertension, BMI and blood sugar. 
However, it also has an independent effect, meaning that overweight, hypertensive and 
diabetic inactive individuals will be at higher risk than a matched population with a higher 
activity level.  
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Many will state that physical activity, diet and overweight go hand in hand, but they are also 
separate risk factors. A person can be skinny looking, but still “fat” on the inside. The 
Mediterranean diet is well known for being heart healthy.  One would think that a low-fat diet 
would be the most beneficial for the cholesterol, but a study showed that adding healthy fats 
through vegetable oils and nuts reduced the cardiovascular risk factors (125).  
Alcohol consumption in moderate amounts is shown to have a beneficial effect on 
cardiovascular disease (24).  
Obesity was early described as an independent risk factor for cardiovascular disease, 
with a dramatically increased disease burden among obese individuals (20, 126).  
As previously described, atherosclerosis is considered an inflammatory disease (3, 62), 
which makes it plausible that the hard outcomes of atherosclerosis, myocardial infarction and 
stroke, are associated with inflammation. Several studies have described this association. A 
study from 1997 shows that CRP predicts myocardial infarction and stroke, and states that the 
reduced risk in individuals using aspirin (acetylsalicylic acid) is due to reduced levels of CRP 
(76). Two years later, a study concluded that CRP is an independent risk factor for 
cardiovascular disease, while another described that CRP adds to the predictive value of 
cholesterol in myocardial infarction (127, 128). Increased CRP also relates to peripheral 
arterial disease (129). Later, other inflammatory biomarkers have been linked to 
cardiovascular disease, like interleukin-6 and soluble intercellular adhesion molecule 1 
(sICAM-1) (130, 131). Acute systemic inflammation, induced by S typhi vaccine, has been 
shown to impair endothelium-dependent vascular dilatation in humans, maybe explaining 
some of the enhanced risk of cardiovascular events in patients with inflammation 
(132).Monocyte count is shown to be a predictor of novel plaque formation (133).  
A study from 2001 concluded that oxidative stress, indicated by a higher response to 
vitamin C, plays a role in both endothelial dysfunction and in coronary artery disease activity 
(134). Another study proposes oxidative stress as the pathogenic mechanism that eventually 
leads to overt diabetes and cardiovascular disease (135).  
Atrial fibrillation is a well-established, independent risk factor for stroke (136). In 
patients with AF, risk of stroke is five-fold increased. The stroke cases attributable to AF 
increased with increasing age, and was 23.5% for those aged 80-89 years in a study with data 
from the Framingham study (90). There has been developed different scoring systems for 
patients with atrial fibrillation to evaluate the need for preventive anticoagulation. One of 
these is the CHA2DS2-VASc score. It incorporates many of the other cardiovascular risk 
factors listed above, like age, sex, diabetes and hypertension, as well as congestive heart 
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failure, previous stroke and vascular disease (137). Atrial fibrillation is a modifiable risk 





Relation between Red Cell Distribution Width and Arterial 
Cardiovascular Disease 
 
Over the last decade, research articles on the relationship between RDW and cardiovascular 
morbidity and mortality have been published in abundance. For the most part, the results point 
in the same direction – describing an association between increasing values of RDW and the 
risk of cardiovascular outcomes and mortality. However, some studies display results showing 
no association. In this section I will thoroughly go through most of the available literature and 
discuss different aspects, including methodological, that might explain the observed results. I 
will primarily focus my attention on the studies I believe to be the strongest, in size and 
methodology, but also mention the smaller studies. I have obtained the literature from the 
MEDLINE database by using the search engines PubMed and google scholar. In PubMed I 
have used medical subheadings (MeSH) to better pinpoint my search. Some of the literature I 
found in the reference list of other key articles. Search words included, but were not limited 
to: “RDW, red cell distribution width, erythrocyte indices, blood cell count, red blood cell, 
risk factor, atherosclerosis, atherosclerotic plaque, peripheral arterial disease, arterial 
cardiovascular disease, myocardial infarction, heart attack, cerebrovascular events, stroke, 
ischemic stroke, and all-cause mortality.  
 
RDW and Atherosclerosis  
As atherosclerosis is a slowly developing condition, often without any symptoms, it tends to 
go under the radar. Hard endpoints like myocardial infarction and stroke are easier to quantify 
and measure, because a person seldom goes through a MI without either dying or going to the 
hospital. For this reason, the relation between RDW and atherosclerosis is harder to get good 
data on compared to MI and stroke. Nonetheless, in the effort to describe the mechanisms 
involved in the relation between RDW and cardiovascular outcomes, the process of 
atherosclerosis, and how it relates to RDW, is perhaps the most crucial step. The available 








Table 1, overview of available literature on the relationship between RDW and 
atherosclerosis 
First author, journal, 
year 




Cross-sectional 156 hypertensive 
patients, 60-85 years 
Higher rate of 
carotid plaque with 
increasing RDW 
values 
Söderholm, Plos One, 
2015 
Cohort 5309 with no 
previous stroke or 
coronary event 
No association 
between RDW and 
presence of plaque. 
Significantly 












principles and practice, 
2015 
Cross-sectional 335 NSTEMI 
patients divided in 




associated with high 
SYNTAX score 
Chaikriangkrai, North 
American journal of 





acute chest pain. No 
known CAD.  
No association 
between RDW and 
coronary 
calcification 
presence or severity 
Khode, Nigerian 
journal of cardiology, 
2014 
Case-control 128 subjects (39 
with MI, 24 with 
stable CAD, 65 
controls) 
No association 













chimica acta, 2011 
Cohort 1489 patients with 




mortality in stepwise 
manner 
Su, journal of thoracic 
disease, 2014 
Systematic review 15 studies on 












Sahin, Turk Kardiyol 
Dern Ars, 2015 
Cross-sectional 326 patients with 
known CAD.  
RDW was a 
predictor of poor 
coronary collateral 
circulation 




Cross-sectional 322 NSTEMI 
patients 




A study published in 2010 in Experimental and Clinical Cardiology by Y. Wen et al. looked 
into RDW and risk of carotid atherosclerosis in patients with hypertension. Carotid 
atherosclerotic plaques were identified using ultrasound in 156 hypertensive inpatients aged 
60-85 years. The population was divided into four categories, and the authors found a 
significantly higher rate of carotid plaque with increasing values of RDW. High baseline 
RDW was also found to be associated with low hemoglobin levels and a high white blood cell 
count. This study was conducted on a small population with hypertension, a known risk factor 
for atherosclerosis, and it could not say anything about the observed relationship independent 
of anemia (138).  
In 2015, Söderholm et al. published a study in Plos One regarding RDW and stroke, 
with some data on the relation between RDW and atherosclerosis as an additional finding. In 
a cohort of 5309 individuals with no previous stroke or coronary event, the presence of 
carotid plaque and intima-media thickness (IMT) was assessed by ultrasound. Logistic 
regression was used to evaluate the relation between sex-specific quartiles of RDW and 
presence of plaque in the common carotid artery. Linear regression was used to assess the 
relation between mean IMT and quartiles of RDW. The regression analyses were adjusted for 
age, systolic and diastolic blood pressure, blood pressure medication, smoking, diabetes, 
alcohol intake, waist circumference, low physical activity, lipid lowering medication, white 
blood cell count, history of atrial fibrillation and heart failure, LDL, HDL and triglycerides. In 
the multivariable adjusted model, the authors did not find any association between RDW 
quartiles and presence of plaque. There was a significantly increased IMT in the common 
carotid artery in the highest quartile of RDW (139). This study was conducted in a large 
sample of previously healthy middle-aged adults, and was well performed. However, it only 
looked at the prevalence of carotid plaque, and did not follow the individuals over time. The 
study does not say anything about RDW and formation or progression of atherosclerotic 
plaques over time.  
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In 2015 Lappegård et al. published data in Thrombosis & haemostasis from the 
Tromsø study, a cohort with similarities to the population described above. The results were 
contradictory.  A population of 4677 was examined with ultrasonographic imaging of the 
carotid artery at two separate occasions 7-8 years apart. Subjects were divided into tertiles 
depending on RDW level. The mean change in total plaque area increased significantly with 
increasing RDW value in multivariable analyses, both with RDW modeled as a categorical 
and continuous variable (140). The adjustment model included many common cardiovascular 
risk factors including hs-CRP levels.  
The following three studies have looked into the relationship between RDW and the 
presence and severity of coronary artery disease. Two of them found no relationship  (141, 
142), whereas the last one did (143) Positive news first. Sahin et al. published a study in 
Medical Principles and Practice on the association between RDW and the severity of 
coronary artery disease in patients with NSTEMI. The severity of CAD was assessed with a 
scoring system called SYNTAX. This scoring system gives “points” based on number of 
lesions, amount of myocardium distal to lesion and morphological features of the lesions 
based on coronary angiography. A total of 335 patients with NSTEMI were enrolled in the 
study. The authors divided the population in two based on the SYNTAX score, and found that 
RDW levels were independently associated with a high score (141). They did not find any 
association between RDW and long-term mortality in the NSTEMI patients. The obvious 
weakness to this study is the population consisting of patients with a previous NSTEMI. To 
determine whether the RDW increased because of the severity of the carotid plaque or vice 
versa is hard because they all had plaque. In my discussion regarding the mechanisms for the 
association between RDW and MI/stroke, this study adds little, as all the subjects already had 
an MI and it’s hard to tell whether the increased RDW was a cause or a consequence of the 
MI.  
Chaikriangkrai et al. published contradictory results in the North American Journal of 
Medical Science in 2014, where 868 consecutive patients presenting with acute chest pain 
were enrolled. The patients did not have known CAD.  The patients went through a multi-
detector cardiac computed tomography scan, and a coronary artery calcium (CAC) score was 
given to rate the CAD. RDW and other clinical characteristics were compared among 
different CAC groups. The researchers did not find a statistically significant association 
between coronary calcification presence or severity, and the hematological indices including 
RDW, MCV and hemoglobin (142).   
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Another study on RDW and CAD published in the Nigerian Journal of Cardiology by Khode 
et al., and reported no association between RDW and CAD (143). However, the authors does 
not say anything about how the CAD was assessed, and it is therefore hard to interpret the 
results. 
Zalawadiya et al. (144)looked at RDW and peripheral artery disease (PAD) in a study 
published in Vascular Medicine in 2012. It was a cross-sectional study of 6950 participants in 
the National Health and Nutrition Examination Survey. Peripheral artery disease was defined 
as an ankle-brachial index below 0.9, and 618 of the participants had such values. With 
increasing quartiles of RDW, a graded increase in prevalent PAD was observed. 4.2% in the 
lowest RDW quartile had PAD, while 13.9% in the highest quartile did. In analysis adjusted 
for age, sex, race, body mass index, hypertension, hyperlipidemia, diabetes, smoking, 
estimated glomerular filtration rate, C-reactive protein, hemoglobin, mean corpuscular 
volume and nutritional factors, they found a significantly increased odds (OR) of 1.19 (95% 
CI 1.06-1.34) with each unit (0.1) increase in RDW. The study population consisted of non-
institutionalized, nationally representative individuals.  
Though the literature on RDW and the formation and progression of atherosclerotic 
plaques is limited, several studies look into how RDW relates to morbidity and mortality in 
patients already known to have CAD. A study published in Clinical Chimica Acta in 2011 by 
Lappé et al. looked into 1489 patients with CAD followed for 8.4-15.2 years. The relation 
between RDW and all-cause mortality was studied using Cox regression. I addition, 449 
patients without CAD were evaluated in the same way. The authors found that RDW, when 
divided into quintiles, predicted all-cause mortality in a stepwise manner, with a multivariable 
adjusted hazard ratio (HR) of 1.21 (95% CI 1.13-1.29) per quintile increase. An even stronger 
relationship was found in the group without CAD where the HR for all-cause mortality was 
1.33 (95% CI 1.15-1.55) per quintile (145). As there are speculations to whether the link 
between RDW and inflammation is the mechanism behind the associations, the study would 
benefit from using controls that were recruited from a healthy population, and not other 
patients, which might suffer from something just as deadly as coronary artery disease.  
In 2014 Su et al. published a systematic review and meta-analysis in the Journal of Thoracic 
Disease looking into the relation between RDW and risk of cardiovascular events, and 
mortality, in patients known with CAD. 15 studies were included in the meta-analysis, with 
only one reporting a negative association (146). The size and quality of the studies varied a 
lot. Study populations ranged from 100-29526 and mean follow-up time from 1 month to 23 
years. Nine of the studies looked at all-cause mortality in CAD-patients. The summary 
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estimate from these studies, comparing the highest RDW category with the lowest, gave a 
pooled risk ratio of 2.20 (95% CI 1.42-3.39). The meta-analysis also indicated a significantly 
increased risk of fatal CVD events (four of the studies investigated this). The pooled RR was 
1.80 (95% CI 1.35-2.41). Eight of the studies looked at non-fatal CVD and gave a pooled 
estimate of 1.86 (95% CI 1.50-2.31). The heterogeneity between the included studies varied 
due to difference in RDW assays, study populations, outcome definitions and how well they 
adjusted for potential confounders. The analysis looking into all-cause mortality had a high 
heterogeneity with I2=93%, while it was 44% for the study of fatal CVD events, and 28% for 
the non-fatal CVD events. I2 says something about the percentage of variance in the analysis 
that is attributable to the study heterogeneity (147). 
  In one retrospective study Şahin et al. looked into how RDW correlates with coronary 
collateral circulation in patients with known CAD. Collateral flow was graded using the 
Rentrop classification in 326 patients. The population was divided into two groups depending 
on their collateral circulation (good: rentrop score 2-3, poor: 0-1).  The total number of 
vessels with >95% stenosis did not differ between the groups. Neither did the Gensini scores. 
The study population was evenly divided, with 155 subjects having good collateral flow, and 
171 bad. Multivariate logistic regression was used, and the adjustment model included 
neutrophil/lymphocyte ratio, MPV, fasting glucose, gamma glutamyl transferase, uric acid, 
and LDL cholesterol. RDW was found to be a predictor of poor coronary collateral 
circulation, with OR of 1.73 (95% CI 1.30-2.29). The authors also found that the proportion 
of subjects with RDW values above the normal limit (14.5% in this study), was significantly 
higher in the group with poor collateral flow (148). All of the patients in this study had CAD, 
and no significant difference in severity was found between the groups. This strengthens the 
theory that the increased RDW might affect the collateral flow directly and is not just due to a 
more severe atherosclerotic disease. Tanboga et al. investigated the same in a population of 
NSTEMI patients instead of patients with CAD. The results were similar, with RDW (OR 
1.52, 95% CI 1.30-1.78) found to be an independent predictor of impaired coronary collateral 
circulation (149).  
The literature is relatively consistent in the results regarding the relationship between 
RDW and atherosclerosis. Defined as either carotid atherosclerosis, peripheral artery disease 
or coronary artery disease, most studies find a positive association between the two. However, 
there are some studies reporting otherwise. The studies vary a lot in quality due to parameters 
such as study populations, methods, and ability to adjust for confounding factors .Only one of 
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the studies above is conducted in a prospective fashion. This means it is hard to tell whether 





RDW and Myocardial Infarction 
As opposed to the data on RDW and atherosclerosis, there are more high-quality prospective 
studies available on the relationship between RDW and MI, as summarized in table 2. Some 
studies also describe the predictive value of RDW in subjects with established heart disease, 
these will be discussed as well.   
 
Table 2, overview of available literature on the relationship between RDW and MI 
First author, 
journal, year 
Study design  Study population Result/conclusion 
Tonelli, Circulation, 
2008 
Post hoc analysis 4111 participants in 
CARE followed for 
median 59,7 months 
Top RDW quartile 
had 56% increased 
risk of fatal coronary 
disease or non-fatal 
MI 
Zalawadiya, The 
American journal of 
cardiology, 2010 





Framingham risk of 
coronary event 
Li, Experimental and 
therapeutic 
medicine, 2015 





Framingham risk of 
coronary event 
Borné, Heart, 2014 Cohort 26820 subjects 
without prior MI 
followed for a mean 
14 years 
RDW significantly 
associated with all 
coronary events and 
fatal coronary 
events, but not with 
non-fatal events.  
Arbel, Thrombosis 




from health registry, 
mean follow-up 5,23 
years 
No association 
between RDW and 
increased risk of 
cardiovascular 
disease in men, 





Cohort  3226 with no history 
of cardiovascular 
disease followed for 







of the American 
heart association, 
2014 
Cohort 25612 participants 
with no previous MI 
followed for median 
15,8 years 
Top RDW quintile 
had 34% increased 
risk of incident MI 





Cohort 1596 patients with 
MI followed for up 
to 12 months 
Markedly increased 






Cohort 691 STEMI patients 
followed for mean 
41,8 moths 
Increased risk of all-
cause mortality in 
top RDW group.  




angina followed for 
up to 3 years 
Increased mortality 













Cohort 859 PCI patients 
followed for median 
time of four years 




artery disease, 2011 
Cohort 2506 STEMI 
patients undergoing 
PCI followed for 
median 21 months 
High RDW group 
associated with in-
hospital death, and 
death after discharge 
 
A study published in Circulation in 2008 by Tonelli et al. was among the first larger studies to 
investigate the association between RDW and myocardial infarction. It was a post hoc 
analysis of the Cholesterol and Recurrent Event study (CARE), a randomized trial of 
pravastatin vs placebo in subjects with previous myocardial infarction. RDW measurements 
was obtained from 4111 participants, which were followed for a median of 59.7 months. Cox 
hazard models were used to analyze the relationship between baseline RDW and different 
cardiovascular outcomes. In a comprehensive adjustment model, subjects in the top RDW 
quartile had a 56% increased risk of fatal coronary disease or non-fatal myocardial infarction, 
when compared to subjects in the lowest quartile (HR 1.56, 95% CI 1.17-2.08) (150). The full 
adjustment model included age, sex, various cardiovascular risk factors, medications and 
kidney function. A clear weakness of this study is the fact that all participants have already 
suffered a myocardial infarction upon enrollment. This means that all subjects have an 
intrinsic risk of a recurrent event, and the generalizability of the results is difficult. No repeat 
measurements of RDW was carried out, so we have to rely on baseline values, and expect that 
they stay about the same for a median of 5 years.  
A study published in The American Journal of Cardiology by Zalawadiya et al. (151) 
evaluated the effect of RDW on coronary heart disease events in 7556 multiethnic, healthy 
and nationally representative subjects recruited from the National Health and Nutrition 
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Examination Surveys (NHANES). Based on the Framingham risk of coronary events, the 
population was divided into three groups, with <10%, 10-20%, or >20% increased 10-year 
risk of a hard coronary heart disease event. The authors found that for every 0.1 increment in 
RDW, there was a significantly increased odds of being in the Framingham middle (OR 1.35 
95% CI 1.27-1.45) or high-risk group (OR 1.38 95% CI 1.25-1.53). This study does not really 
say anything concrete about how high RDW values relate to the risk of future myocardial 
infarctions, because it lacks hard end points. It illustrates how RDW correlates to the variables 
included in the Framingham risk assessment, like blood pressure, cholesterol, smoking and 
age.  
A study by Li et al. (152) had a similar approach when they evaluated the relation 
between RDW and the Framingham risk score in patients with known coronary artery disease. 
The study material consisted of 392 patients undergoing coronary angiography. In a 
multivariable linear regression model they found an association between higher levels of 
RDW and an elevated Framingham risk score.  
In 2014 Borné et al. (153) published data from a large cohort study in Heart showing a 
relationship between RDW and incidence of coronary events. A total of 26820 study 
participants in the Malmö Diet and Cancer study without prior myocardial infarction or stroke 
had RDW measured at baseline, and were followed for a mean of 14 years. During follow-up, 
1995 participants had a non-fatal or fatal coronary event. Subjects were divided into sex-
specific quartiles of RDW. Cox regression models were used to assess risk of coronary events 
across quartiles of RDW. An acute coronary event was defined as either a hospital diagnosis 
of acute myocardial infarction, or death due to ischemic heart disease. In adjusted analyses, 
baseline RDW was significantly associated with risk of fatal coronary events (HR 1.82, 95% 
CI 1.35-2.44), but not with non-fatal coronary events (HR 0.96, 95% CI 0.82-1.12). In this 
study, a fatal coronary event was defined as death within 28 days after the occurrence. As 
RDW is highly associated to anemia, all anemic subjects (n=826) were excluded, and the 
same analyses were run. The risk estimates remained more or less the same in the non-anemic 
population (HR1.81, 95% CI 1.35-2.45). The authors found a significant interaction between 
RDW and smoking, leading to analyses stratified for smoking status. Among non-smokers, 
the risk of a fatal coronary event was attenuated compared to the analyses in the whole 
population, but still significant with a 48% increased risk (HR 1.48, 95 CI 1.04-2.10) when 
comparing the fourth and first RDW quartile. As for many of the other studies, RDW was 
only measured at baseline, leaving little knowledge about how changes in RDW affects risk 
estimates over time. 
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Comparable to the study discussed above, Arbel et al. (154) found no association 
between RDW and increased risk of cardiovascular events in men, and a slightly increased 
risk in women, in a registry-based, retrospective cohort study of 225006 subjects. The study 
describes a relation between RDW and all-cause mortality, but says nothing about 
cardiovascular mortality. Subjects with RDW >17% were compared to subjects with RDW 
<13%. Over a mean follow-up of 5.2 years, the HR of a major cardiovascular event was 1.08 
(95% CI 0.82-1.41) for males, and 1.26 (95% CI 1.03-1.52) for females. The multivariable 
model included adjustments for age, hemoglobin, blood glucose, HDL, triglycerides, BMI, 
diabetes, hypertension, smoking and COPD. In analyses of all-cause mortality they found a 
strong association with increasing RDW. Again comparing RDW >17% to RDW <13%, the 
authors found that men had a HR of 4.57 (95% CI 3.35-6.24), and women a HR of 3.26 (95% 
CI 2.49-4.28) for all-cause mortality. After exclusion of anemic subjects, the association was 
strengthened. This study boasts some strong numbers with 225006 participants, and 21939 
cases of incident major cardiovascular events. However, the study participants are not 
representative for the general healthy population. They are all above the age of 40, and 
selected from a health register where all participants had their blood drawn sometime within 
the last year upon inclusion. In other words, they were all at the hospital for some reason, and 
probably have some intercurrent illness. Another big issue is the broad definition of a major 
cardiovascular event in this study, as it includes patients with ischemic heart disease, chronic 
heart failure, peripheral vascular disease, cerebrovascular event, transient ischemic attack, or 
patients that underwent percutaneous coronary intervention or coronary artery bypass surgery. 
All in all, there can’t be drawn any specific conclusions about RDWs impact on the risk of 
myocardial infarction from this study. 
In a community cohort in Taiwan, RDW was measured in 3226 individuals with no 
history of cardiovascular disease (155). The study participants were followed for a median 
time of 15.9 years. Chen et al. published findings from this cohort regarding RDW and risk of 
coronary disease in the American Journal of Epidemiology in 2010. In this study the term 
coronary heart disease included study participants with a nonfatal myocardial infarction, fatal 
coronary heart disease, or participants that were hospitalized for percutaneous coronary 
intervention or coronary bypass surgery. Subjects were divided into quartiles according to 
their RDW values, and Cox proportional hazard models were used to evaluate the associations 
between baseline RDW and risk of future cardiovascular disease or death. During follow-up, 
151 participants developed coronary heart disease. The crude analyses did not yield 
convincing evidence with a HR of 1.16 (95% CI 0.76-1.78) when comparing the top quartile 
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(RDW >13.7%) with the bottom quartile (RDW ≤ 12.7%). The association was further 
weakened after adjustments for confounding variables, with a HR of 1.05 (95% CI 0.65-1.68).  
Again, this was not a study looking specifically into myocardial infarctions. 
In a study by Skjelbakken et al. (156) the specific association between RDW and 
myocardial infarction was studied in a large cohort with subjects recruited from the general 
population. During a median follow-up of 15.8 years, 1779 of the 25612 study participants 
suffered a first-ever myocardial infarction. In categorical analyses, the bottom RDW quintile 
was used as the reference group. In a multivariable model adjusted for common 
cardiovascular risk factors, subjects in the top quintile had 34% increased risk of an incident 
myocardial infarction (HR 1.34, 95% CI 1.11-1.60). The risk estimate was further increased 
to 71% (HR 1.71, 95% CI 1.34-2.20) when subjects with RDW values above the 95th 
percentile were compared to those in the bottom quintile. In continuous analyses, a 1% 
increase in RDW yielded a 16% increased risk of myocardial infarction (HR 1.16, 95% CI 
1.11-1.21). Analyses were stratified for smoking status, this adjustment increased the risk 
estimate among smokers while decreasing it among non-smokers. Risk estimates remained 
essentially the same after exclusion of anemic subjects. Like all the other studies to date, this 
study did not have repeated measurements of RDW.   
Several studies have investigated the value of RDW as a prognostic marker in 
myocardial infarction patients. Lee et al. (157) investigated the association between RDW and 
major adverse cardiac events (MACE) in patients with previous myocardial infarction. 
Patients with MI were followed for up to 12 months with MACE endpoints being either death 
or a second nonfatal MI. In total, 1596 patients were divided into quartiles depending on their 
admission RDW value. In Cox proportional hazard models adjusting for confounding 
variables the HR for MACE when comparing the top with the bottom RDW quartile was 6.18 
(95% CI 2.10-18.21) (157).  
Sun et al. (158) followed 691 STEMI patients free of heart failure for a mean time of 
41.8 months. The participants were divided into two groups depending on RDW value. 
Multivariable analyses showed that subjects in the top group had a hazard ratio of 3.43 (95% 
CI 1.17-8.32) for all-cause mortality when compared to the bottom group (158). The study 
had a low number of events, with only 47 patients dying during follow-up.  
A study by Mehmet Gul et al. (159) followed 310 patients with NSTEMI and unstable 
angina for up to 3 years after discharge. Participants were divided into tertiles depending on 
RDW value. In Kaplan-Meier survival analysis the cumulative mortality rate during 3 years 
after hospital discharge was 5.6% in the lowest RDW, and 19% in the top tertile.  
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A similar study by Azab et al. (160) followed 619 NSTEMI patients after discharge. After 
adjustments for confounding variables they found that patients in the top RDW tertile had a 
30% 4-year mortality rate vs 7% in the bottom tertile (160). Each unit increase in RDW 
yielded a 10% increased risk of 4-year all-cause mortality (HR 1.10, 95% CI 1.004-1.213).  
Two studies have described the prognostic value of RDW in patients admitted for 
percutaneous coronary intervention (PCI). In a study by Poludasu et al. (161) published in 
Thrombosis and Haemostasis in 2009, 859 PCI patients were followed for a median time of 
four years and 95 died. In multivariate analyses, high RDW was found to be a strong predictor 
of mortality in patients with hemoglobin >10.4, but not in those with Hb <10.4. The authors 
argue that severe anemia in itself is a strong predictor of adverse outcome in PCI patients, and 
therefore the predictive power of RDW is reduced in this subgroup. The other comparable 
study by Uyarel et al. (162) followed 2506 STEMI patients undergoing PCI for a median time 
of 21 months. The study population was divided into a high and a low RDW group. High 
RDW was associated with both in-hospital death, and death after discharge from the hospital.  
To sum up, the evidence is contradictory with regard to the relation between RDW and 
incident myocardial infarction. Large population-based cohort studies have shown varying 
results. One large cohort studies did not find any association between RDW and future 
coronary event, while one found borderline evidence, and one presented definite evidence. 
There were some important differences in the definition of cases between the three studies. In 
the study by Chen et al. from the Taiwan cohort, a coronary event was widely defined and 
included clinically stable patients admitted for coronary artery bypass surgery or percutaneous 
coronary intervention. Even with the wide definition, the case numbers were far weaker than 
in the other two studies. In the study by Borné et al. the events only included acute myocardial 
infarctions, but they were defined as “fatal” if a subject died within the first 28 days after the 
event. In analyses of non-fatal events, they found no association, but in analyses of all the 
events put together, the risk estimates showed an association. Those results are more 
comparable to the study by Skjelbakken et al. which also looked at fatal/non-fatal myocardial 
infarctions combined, and reported a clear association between RDW and events. The latter 
study has a more generalizable study population compared to the study by Borné, and a more 
precise definition of outcome event compared to the study by Chen. Based on the studies 
presented I believe it’s reasonable to conclude that there is a clear association between RDW 
and myocardial infarctions in western world populations. The disease distribution is very 




Studies investigating all-cause mortality in patients with heart disease, all point in the 




RDW and Stroke 
The available evidence on the relationship between RDW and stroke is summarized in table 3. 
 
Table 3, overview of available literature on the relationship between RDW and Stroke 
First author, journal, 
year 
Study design  Study population Result/conclusion 
Tonelli, Circulation, 
2008 
Post hoc analysis 4111 participants in 
CARE followed for 
median 59,7 
months 
Top RDW quartile 
HR of 2.58 for 
stroke compared to 
bottom 
Söderholm, Plos One, 
2015 
Cohort 26879 previously 
healthy subjects 
followed for 
median 15,2 years 
Top RDW quartile 
had a 31% increased 
risk of stroke 
compared to bottom 
Lappegård, Thrombosis 
& haemostasis, 2015 
Cohort 25992 subjects 
from the general 
population. Median 
follow up 15,8 
years 
Subjects in top 
RDW quintile had a 
37% higher risk of 
incident stroke 
compared to bottom 
Ramírez-Moreno, 
International journal of 
stroke, 2013 





RDW and risk of 
stroke 




Cohort  133 heart failure 
patients followed 
for 1 year, 14 
stroke events 
RDW above 15,2% 
predicted stroke 
with 87% sensitivity 
and 74% specificity  
Saliba, The American 
journal of medicine, 
2014 




RDW and stroke 
 
The previously described study by Tonneli et al. additionally investigated the relationship 
between RDW and stroke (150). In fully adjusted analyses, subjects in the top RDW quartile 
had a hazard ratio for stroke of 2.58 (95% CI 1.47-4.55) when compared to the bottom 
quartile. As discussed above, this study was not conducted in a healthy population, but in 
CARE study participants with a previous myocardial infarction.  
Söderholm et al. (139) published a study on RDW and atherosclerosis, but the primary 
focus on the study was stroke. This large (n=26879), population-based cohort of previously 
healthy subjects provides the strongest evidence on the relation between RDW and stroke thus 
far. The population was divided into quartiles of RDW and followed for a median time of 
15.2 years. During follow-up 1869 participants suffered a first ever stroke. Compared to the 
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reference bottom quartile, subjects in the top quartile had a 31% increased risk of total stroke 
(HR 1.31, 95% CI 1.11-1.54) in a multivariable adjusted model. The results were essentially 
the same in analyses looking specifically into cerebral infarctions (n=1544). The association 
was borderline significant for intracerebral hemorrhage (HR 1.44, 95% CI 0.90-2.30), while 
there was no association between RDW values and subarachnoid hemorrhage (HR 0.94, 95% 
CI 0.43-2.07). A limited number of events, and thereby low statistical power, might explain 
this, as only 75 subjects suffered a subarachnoid hemorrhage during follow-up.  
Lappegård et al. published very similar results in Thrombosis & haemostasis (163). 
The cohort consisted of 25992 subjects recruited from a general population, aging from 25 
years and up. During a median follow-up of 15.8 years, 1152 participants experienced a first-
ever stroke. When comparing top with bottom quintiles in a multivariable adjusted model, 
subjects with the highest RDW values had a 37% increased risk of stroke. Subjects in the top 
95th percentile had a 55% increased risk. The risk estimates remained the same after exclusion 
of subjects with anemia. There was no association between RDW and hemorrhagic strokes in 
subtype analyses, but these analyses were limited by weak numbers. RDW was not associated 
with risk of all-cause mortality within one year or during the entire follow-up, after incident 
stroke.   
A case-control study by Ramírez-Moreno et al. (164) investigated 224 incident 
ischemic stroke events and 224 randomly selected controls from the same source population. 
The population was divided into RDW quartiles, using the lowest quartile as a reference 
group. Subjects in the fourth quartile had an OR of 5.9 (95% CI 3.1-11.4). The authors also 
found a continuous dose-response relationship between RDW and risk of stroke.  
Kaya et al. (165) followed 133 patients with heart failure (NYHA class 1-3) for 1 year 
until 14 of them developed a stroke. Receiver-operating characteristics (ROC) curves were 
used to estimate sensitivity and specificity of RDW for predicting stroke. They found that 
RDW above or equal to 15.2% on admission had a 87% sensitivity and a 74% specificity in 
predicting stroke. An association between RDW and stroke was also described in a registry 
based study with subjects with atrial fibrillation (166), while a large cohort study found a 
relationship between RDW and atrial fibrillation (167).  
 All the studies presented show a positive relationship between RDW and risk of stroke 
events. In the studies looking into subtypes of stroke events, there were no associations 






Underlying mechanisms for the observed association 
While numerous studies show relationships between RDW and various disease outcomes, 
none have been able to conclude why we observe these associations. Does increased RDW 
have a direct impact on pathophysiological mechanisms, or is it merely a marker of disease, 
reflecting something else going on in the body? 
 
RDW as a direct influence on disease mechanism 
Increased RDW reduces red cell deformability, which in turn can impair blood flow in the 
microcirculation, leading to hypoxia and increase risk of cardiovascular disease events (168). 
Such hypoxia might also stimulate to the release of EPO and thereby have an effect on 
erythropoiesis. A study from 1984 concludes that both red cell deformability and red cell size 
plays a role in how platelets interact with the vessel wall, and thereby affects thrombus 
formation (169).  
Erythrocytes contain a substantial amount of cholesterol in their membranes, which 
contributes in the progression of atherosclerotic plaques (170). In addition to adding on as 
building blocks, the accumulation of free cholesterol within the atherosclerotic plaque makes 
it more vulnerable to rupture (171). The erythrocyte membrane is regarded as an important 
source of this cholesterol (172, 173). Cholesterol content in erythrocyte membranes has been 
described as a novel biomarker of clinical instability in coronary artery disease, and increased 
RDW has been associated to this increased cholesterol content (174). This might be one way 
to explain both the association between RDW and atherosclerosis formation/progression, and 
it’s relation to myocardial infarctions and stroke.  
 
RDW as a marker of some other underlying cause 
Since RDW is a numeric concept with its value calculated from something else (MCV), and 
not something that can be measure directly, one can suppose that its relationship to disease 
must be mediated by other factors. This theory is supported by the fact that RDW is 
associated with such broad specter of disease. It is unreasonable to think that RDW has a 
distinct impact on all pathophysiological mechanisms in diseases ranging from dementia to 
myocardial infarction, but rather describes some sort of disease presence.   
Numerous studies on populations with various conditions/diseases show a relationship 
between RDW and risk of mortality. This supports the theory that RDW reflects an 
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underlying disease process going on in the body, and that this underlying condition makes the 
subject more vulnerable.  One way to assess such an “underlying disease” is through 
inflammatory markers. As described above, both RDW and cardiovascular disease outcomes 
are heavily associated with several markers of inflammation, including CRP, white blood cell 
count and interleukins. In contradiction, studies have also shown that RDW is associated to 
disease outcome and mortality after adjustments for inflammatory markers. An association 
between RDW and mortality was seen in a selected population with normal CRP and white 
blood cell count levels (175).  
In the CARE study (176), there was an association between RDW and myocardial 
infarction. Subjects in the top RDW quartile had a 56% increased risk of fatal or non-fatal 
myocardial infarction. In the same population, analyses of the relation between CRP and 
myocardial infarction was conducted, with very similar results. Subjects in the highest CRP 
quintile had a 77% higher relative risk of a recurrent coronary event. The relative risks were 
matched for age and sex, but not adjusted for any other confounding variables.  
If the link between RDW and cardiovascular disease were to be explained by inflammation, 
how might inflammation alter RDW levels? It is stated that interleukin-6 stimulates 
erythropoiesis (177). The same has been shown for IL-12 (178). Stimulation of erythropoiesis 
will lead to release of more immature erythrocytes into the blood stream. These are larger in 
size and will thereby increase the RDW.  
On the other hand, studies also describe an inhibiting effect on the erythropoiesis 
induced by inflammatory cytokines TNF-alfa, IFN-gamma (179). Pro-inflammatory cytokines 
cause a deficiency in erythropoietin and thereby mediates anemia. Whether such a situation 
might lead to an increase in RDW, is uncertain. The oldest, smallest erythrocytes will in time 
die, leading to a shift in size distribution. This might actually cause a reduction in RDW by 
further evening out the size of the remaining erythrocytes. Another option is that the bone 
marrow tries to compensate for the anemic situation by prematurely releasing immature, 
large, blood cells (reticulocytes) due to increased erythropoietin release following the anemic 
state, which in turn will increase the RDW. The anemic state has a stimulating effect on EPO 
production which might suppress the apparent inhibiting effect of the pro-inflammatory 
cytokines.  
Increased levels of reactive oxygen species (ROS), leads to ineffective erythropoiesis 
(180). Uncontrolled increase in ROS can lead to hemolysis and in turn an increase in RDW by 
the mechanisms described above (181).   
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The clinical use of RDW 
Many theories exist regarding the reason why RDW is associated with such a wide specter of 
disease. In the literature, a risk factor for a disease outcome is described as a factor that 
precedes the disease, predicts it, and that is directly involved in the biological causal pathway 
of the disease (182). A biomarker, on the other hand, is a biological indicator of some process 
involved in the disease development. Based on this definition, there are doubts to the whether 
the variation in size of red blood cells is a risk factor in any of the diseases described above. 
However, the literature more or less agrees in purposing RDW as a marker of some 
underlying disease/inflammatory state. With inflammation playing a key role in 
atherogenesis, this makes it reasonable to call RDW a biomarker for the diseases described 
above. This way, the use of RDW in risk stratification has a true potential. RDW has been 
shown valuable in prediction of both first time events and recurrent events/mortality. For 
instance, RDW could be implemented in established risk calculators for disease outcome, 
severity, prognosis etc. As a biomarker it has great potential value because it is independent of 
many well known risk factors, and could thereby add new information. As it is inexpensive 
and readily available, it might be a variable that clinicians should pay more attention to, and 
more often include in the blood works of their patients. Nonetheless, one must explore and 
clarify the underlying mechanisms for the observed relationships in order to introduce 





RDW is an inexpensive lab value readily available from a standard blood cell count. It is 
related to atherosclerosis, myocardial infarction and stroke. In this literature study I have 
described the basic epidemiology and pathophysiology of these disease entities, and 
afterwards presented and discussed available research on the topic. This all gave a 
comprehensive background for the discussion on why we see these relationships between 
RDW and cardiovascular disease. The underlying mechanism for the associations remains 
unclear, but it is heavily argued that RDW is a marker of some underlying disease 
state/inflammatory state. Thereby, RDW is a potential novel biomarker for risk stratification 







1. Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. 
Circulation 2001; 104(3): 365-72. 
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 
362(6423): 801-9. 
3. Ross R. Atherosclerosis — An Inflammatory Disease. New England Journal of 
Medicine 1999; 340(2): 115-26. 
4. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, 
region, and age: statistics from World Health Organisation and United Nations. International 
journal of cardiology 2013; 168(2): 934-45. 
5. Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 
2014: epidemiological update. Eur Heart J 2014; 35(42): 2929. 
6. Mannsverk J, Wilsgaard T, Njølstad I, et al. Age and gender differences in incidence 
and case fatality trends for myocardial infarction: a 30-year follow-up. The Tromsø Study. 
European journal of preventive cardiology 2012; 19(5): 927-34. 
7. Mannsverk J, Wilsgaard T, Mathiesen EB, et al. Trends in Modifiable Risk Factors are 
Associated With Declining Incidence of Hospitalized and Non-Hospitalized Acute Coronary 
Heart Disease in a Population. Circulation 2015: CIRCULATIONAHA. 115.016960. 
8. Hackett ML, Duncan JR, Anderson CS, et al. Health-Related Quality of Life Among 
Long-Term Survivors of Stroke: Results From the Auckland Stroke Study, 1991–1992. 
Stroke; a journal of cerebral circulation 2000; 31(2): 440-7. 
9. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-Term Disability After First-Ever 
Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990. 
Stroke; a journal of cerebral circulation 2002; 33(4): 1034-40. 
10. Go AS, Mozaffarian D, Roger VL, et al. Executive Summary: Heart Disease and 
Stroke Statistics—2013 Update: A Report From the American Heart Association. Circulation 
2013; 127(1): 143-52. 
11. Handa N, Matsumoto M, Maeda H, et al. Ischemic stroke events and carotid 
atherosclerosis results of the Osaka follow-up study for ultrasonographic assessment of 
carotid atherosclerosis (the OSACA Study). Stroke; a journal of cerebral circulation 1995; 
26(10): 1781-6. 
12. WHO. The top 10 causes of death. http://wwwwhoint/mediacentre/factsheets/fs310/en/ 
2014. 
13. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and 
control, World Health Organization; 2011. 
14. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. 
Bmj 1989; 298(6676): 789-94. 
15. Kannel WB, McGee DL. Diabetes and Glucose Tolerance as Risk Factors for 
Cardiovascular Disease: The Framingham Study. Diabetes care 1979; 2(2): 120-6. 
16. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. 
JAMA 1996; 275(20): 1571-6. 
17. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, Other Risk Factors, and 12-Yr 
Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial. 
Diabetes care 1993; 16(2): 434-44. 
18. Michel de Lorgeril M, Salen P, Martin J-L, et al. Mediterranean diet, traditional risk 
factors, and the rate of cardiovascular complications after myocardial infarction. Heart failure 
1999; 11: 6. 
19. Powell KE, Thompson PD, Caspersen CJ, et al. Physical activity and the incidence of 
coronary heart disease. Annual review of public health 1987; 8(1): 253-87. 
46 
 
20. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor 
for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart 
Study. Circulation 1983; 67(5): 968-77. 
21. LaRosa J, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the 
evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement 
by the American Heart Association and the National Heart, Lung, and Blood Institute. The 
Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81(5): 
1721. 
22. Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering 
in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 
(4S). The Lancet 1994; 344(8934): 1383-9. 
23. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for 
coronary heart disease. The Lancet 1992; 339(8808): 1523-6. 
24. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with 
selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 
342. 
25. Nagajothi NMD, Braverman AMD. Elevated Red Cell Distribution Width in the 
Diagnosis of Thrombotic Thrombocytopenic Purpura in Patients Presenting with Anemia and 
Thrombocytopenia. Southern Medical Journal 2007; 100(3): 257-9. 
26. Monzon CM, Beaver BD, Dillon TD. Evaluation of Erythrocyte Disorders With Mean 
Corpuscular Volume (MCV) and Red Cell Distribution Width (RDW). Clinical Pediatrics 
1987; 26(12): 632-8. 
27. Rodak BF, Fritsma GA, Doig K. Hematology: Clinical Principles and Applications, 
Saunders Elsevier; 2007. 
28. Aulakh R, Sohi I, Singh T, et al. Red cell distribution width (RDW) in the diagnosis of 
iron deficiency with microcytic hypochromic anemia. Indian journal of pediatrics 2009; 
76(3): 265-8. 
29. Şenol K, Saylam B, Kocaay F, et al. Red cell distribution width as a predictor of 
mortality in acute pancreatitis. The American Journal of Emergency Medicine 2013; 31(4): 
687-9. 
30. Balta S, Demirkol S, Akgul EO. Red blood cell distribution width is predictive of 
mortality in trauma patients. Journal of Trauma and Acute Care Surgery 2013; 75(2): 345-6. 
31. Weuve J, Mendes de Leon CF, Bennett DA, et al. The red cell distribution width and 
anemia in association with prevalent dementia. Alzheimer disease and associated disorders 
2014; 28(2): 99-105. 
32. Kim CH, Park JT, Kim EJ, et al. An increase in red blood cell distribution width from 
baseline predicts mortality in patients with severe sepsis or septic shock. Critical Care 2013; 
17(6): R282-R. 
33. Lippi G, Sanchis-Gomar F, Danese E, et al. Association of red blood cell distribution 
width with plasma lipids in a general population of unselected outpatients. Kardiol Pol 2013; 
71(9): 931-6. 
34. Lippi G, Targher G, Salvagno GL, et al. Increased red blood cell distribution width 
(RDW) is associated with higher glycosylated hemoglobin (HbA1c) in the elderly. Clin Lab 
2014; 276: 174-83. 
35. Yu HM, Park KS, Lee JM. The value of red blood cell distribution width in subclinical 
hypothyroidism. Arquivos Brasileiros de Endocrinologia & Metabologia 2014; 58(1): 30-6. 
36. Meynaar I, Knook A, Coolen S, et al. Red cell distribution width as predictor for 
mortality in critically ill patients. Neth J Med 2013; 71(9): 488-93. 
47 
 
37. Braun E, Kheir J, Mashiach T, et al. Is elevated Red cell distribution width a 
prognostic predictor in adult patients with community acquired Pneumonia? BMC infectious 
diseases 2014; 14(1): 129. 
38. Seyhan EC, Özgül MA, Tutar N, et al. Red blood cell distribution and survival in 
patients with chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive 
Pulmonary Disease 2013; 10(4): 416-24. 
39. Yang W, Huang H, Wang Y, et al. High red blood cell distribution width is closely 
associated with nonalcoholic fatty liver disease. European Journal of Gastroenterology & 
Hepatology 2014; 26(2): 174-8. 
40. Mucsi I, Ujszaszi A, Czira ME, et al. Red cell distribution width is associated with 
mortality in kidney transplant recipients. International urology and nephrology 2014; 46(3): 
641-51. 
41. Zöller B, Melander O, Svensson P, et al. Red cell distribution width and risk for 
venous thromboembolism: A population-based cohort study. Thrombosis Research 2014; 
133(3): 334-9. 
42. Adamsson Eryd S, Borné Y, Melander O, et al. Red blood cell distribution width is 
associated with incidence of atrial fibrillation. Journal of internal medicine 2014; 275(1): 84-
92. 
43. Lippi G, Targher G, Montagnana M, et al. Relation Between Red Blood Cell 
Distribution Width and Inflammatory Biomarkers in a Large Cohort of Unselected 
Outpatients. Archives of Pathology & Laboratory Medicine 2009; 133(4): 628-32. 
44. Fujita B, Strodthoff D, Fritzenwanger M, et al. Altered red blood cell distribution 
width in overweight adolescents and its association with markers of inflammation. Pediatric 
Obesity 2013; 8(5): 385-91. 
45. Özcan F, Turak O, Durak A, et al. Red cell distribution width and inflammation in 
patients with non-dipper hypertension. Blood Pressure 2013; 22(2): 80-5. 
46. Öztürk ZA, Ünal A, Yiğiter R, et al. Is increased red cell distribution width (RDW) 
indicating the inflammation in Alzheimer's disease (AD)? Archives of Gerontology and 
Geriatrics 2013; 56(1): 50-4. 
47. Förhécz Z, Gombos T, Borgulya G, et al. Red cell distribution width in heart failure: 
Prediction of clinical events and relationship with markers of ineffective erythropoiesis, 
inflammation, renal function, and nutritional state. American Heart Journal 2009; 158(4): 
659-66. 
48. Miyamoto K, Inai K, Takeuchi D, et al. Relationships among red cell distribution 
width, anemia, and interleukin-6 in adult congenital heart disease. Circulation Journal 2015; 
79(5): 1100-6. 
49. Dogan S, Celikbilek M, Zararsiz G, et al. Red blood cell distribution width as a non-
invasive marker for the assessment of inflammation in non-alcoholic steatohepatitis. Hepato-
gastroenterology 2014; 62(138): 393-8. 
50. Maes M, Scharpe S, Cooreman W, et al. Components of biological, including 
seasonal, variation in hematological measurements and plasma fibrinogen concentrations in 
normal humans. Experientia 1995; 51(2): 141-9. 
51. Dzierzak E, Philipsen S. Erythropoiesis: development and differentiation. Cold Spring 
Harbor perspectives in medicine 2013; 3(4): a011601. 
52. Hoffbrand V, Moss PA. Essential haematology, John Wiley & Sons; 2011. 
53. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol 
Rev 1992; 72(2): 449-89. 
54. Malik J, Kim AR, Tyre KA, et al. Erythropoietin critically regulates the terminal 




55. Josse M, Touboul P, Mas J, et al. Prevalence of asymptomatic internal carotid artery 
stenosis. Neuroepidemiology 1987; 6(3): 150-2. 
56. Salonen R, Seppänen K, Rauramaa R, et al. Prevalence of carotid atherosclerosis and 
serum cholesterol levels in eastern Finland. Arteriosclerosis, Thrombosis, and Vascular 
Biology 1988; 8(6): 788-92. 
57. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in 
asymptomatic teenagers and young adults evidence from intravascular ultrasound. Circulation 
2001; 103(22): 2705-10. 
58. Joakimsen O, Bønaa KH, Stensland-Bugge E, et al. Age and sex differences in the 
distribution and ultrasound morphology of carotid atherosclerosis The Tromsø Study. 
Arteriosclerosis, thrombosis, and vascular biology 1999; 19(12): 3007-13. 
59. Olin J, Melia M, Young J, et al. Prevalence of atherosclerotic renal artery stenosis in 
patients with atherosclerosis elsewhere. The American journal of medicine 1990; 88(1N): 
46N-51N. 
60. Ouriel K. Peripheral arterial disease. The lancet 2001; 358(9289): 1257-64. 
61. Kumar V, Abbas AK, Aster JC. Robbins basic pathology, Elsevier Health Sciences; 
2012. 
62. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 
105(9): 1135-43. 
63. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human 
fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation 
of low density lipoprotein and its oxidation precede monocyte recruitment into early 
atherosclerotic lesions. The Journal of Clinical Investigation 1997; 100(11): 2680-90. 
64. Forfang K, Istad H, Wiseth R. Kardiologi: klinisk veileder, Gyldendal Akademisk; 
2011. 
65. Hall JE. Guyton and Hall textbook of medical physiology, Elsevier Health Sciences; 
2015. 
66. Cybulsky MI, Gimbrone M. Endothelial expression of a mononuclear leukocyte 
adhesion molecule during atherogenesis. Science 1991; 251(4995): 788-91. 
67. Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, 
and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis, Thrombosis, 
and Vascular Biology 1986; 6(2): 131-8. 
68. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human 
atherosclerotic plaque. The American journal of pathology 1989; 135(1): 169. 
69. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. New 
England Journal of Medicine 2005; 352(16): 1685-95. 
70. van der Wal AC, Becker A, Van der Loos C, et al. Site of intimal rupture or erosion of 
thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process 
irrespective of the dominant plaque morphology. Circulation 1994; 89(1): 36-44. 
71. Frostegård J, Ulfgren A-K, Nyberg P, et al. Cytokine expression in advanced human 
atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating 
cytokines. Atherosclerosis 1999; 145(1): 33-43. 
72. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” 
coronary artery disease. The American journal of cardiology 1990; 65(3): 168-72. 
73. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive 
protein and serum amyloid a protein in severe unstable angina. New England journal of 
medicine 1994; 331(7): 417-24. 
74. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum 
levels of troponin T and C-reactive protein on admission in patients with unstable angina 
pectoris. The American journal of cardiology 1998; 82(6): 715-9. 
49 
 
75. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and 
troponin T in patients with unstable angina: a comparative analysis. Journal of the American 
College of Cardiology 2000; 35(6): 1535-42. 
76. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of 
cardiovascular disease in apparently healthy men. New England journal of medicine 1997; 
336(14): 973-9. 
77. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. New England Journal of 
Medicine 2000; 342(12): 836-43. 
78. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 
update A report from the American Heart Association. Circulation 2010; 121(7): e46-e215. 
79. Yusuf S, Reddy S, Ôunpuu S, et al. Global burden of cardiovascular diseases part II: 
variations in cardiovascular disease by specific ethnic groups and geographic regions and 
prevention strategies. Circulation 2001; 104(23): 2855-64. 
80. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. 
Journal of the American College of Cardiology 2007; 50(22): 2173-95. 
81. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden 
cardiac ischemic death. New England Journal of Medicine 1984; 310(18): 1137-40. 
82. Mach F, Schönbeck U, Bonnefoy J-Y, et al. Activation of monocyte/macrophage 
functions related to acute atheroma complication by ligation of CD40 induction of 
collagenase, stromelysin, and tissue factor. Circulation 1997; 96(2): 396-9. 
83. Amento EP, Ehsani N, Palmer H, et al. Cytokines and growth factors positively and 
negatively regulate interstitial collagen gene expression in human vascular smooth muscle 
cells. Arteriosclerosis, Thrombosis, and Vascular Biology 1991; 11(5): 1223-30. 
84. Arroyo LH, Lee RT. Mechanisms of plaque rupture; 1999. 
85. Little WC, Constantinescu M, Applegate R, et al. Can coronary angiography predict 
the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary 
artery disease? Circulation 1988; 78(5): 1157-66. 
86. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of 
coronary artery disease and the development of myocardial infarction. Journal of the 
American College of Cardiology 1988; 12(1): 56-62. 
87. Levine GN, Keaney Jr JF, Vita JA. Cholesterol reduction in cardiovascular disease—
clinical benefits and possible mechanisms. New England Journal of Medicine 1995; 332(8): 
512-21. 
88. Asplund K, Stegmayr B, Peltonen M. From the twentieth to the twenty-first century: a 
public health perspective on stroke. Cerebrovascular disease-pathophysiology, diagnosis and 
management Boston: Blackwell Science 1998: 901-18. 
89. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes 
of ischemic stroke the german stroke data bank. Stroke; a journal of cerebral circulation 2001; 
32(11): 2559-66. 
90. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for 
stroke: the Framingham Study. Stroke; a journal of cerebral circulation 1991; 22(8): 983-8. 
91. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. 
Neuropharmacology 2008; 55(3): 310-8. 
92. Association AH. 
http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/IschemicClots/I
schemic-Strokes-Clots_UCM_310939_Article.jsp. 
93. Castelli WP. Epidemiology of coronary heart disease: The Framingham study. The 
American journal of medicine 1984; 76(2, Part A): 4-12. 
50 
 
94. Jousilahti P, Puska P, Vartiainen E, et al. Parental history of premature coronary heart 
disease: an independent risk factor of myocardial infarction. Journal of clinical epidemiology 
1996; 49(5): 497-503. 
95. Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor 
of death due to cardiovascular disease. Circulation 1984; 69(6): 1065-9. 
96. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events 
after myocardial infarction in patients with average cholesterol levels. New England Journal 
of Medicine 1996; 335(14): 1001-9. 
97. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. New England Journal of Medicine 1995; 
333(20): 1301-8. 
98. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events 
with lovastatin in men and women with average cholesterol levels: results of 
AFCAPS/TexCAPS. Jama 1998; 279(20): 1615-22. 
99. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of Coronary Heart Disease 
Using Risk Factor Categories. Circulation 1998; 97(18): 1837-47. 
100. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood 
pressure levels in 6 European countries, Canada, and the United States. Jama 2003; 289(18): 
2363-9. 
101. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. The 
American journal of cardiology 2000; 85(2): 251-5. 
102. MacMahon S, Peto R, Collins R, et al. Originally published as Volume 1, Issue 
8692Blood pressure, stroke, and coronary heart disease. The Lancet 1990; 335(8692): 765-74. 
103. Jennrich R. Age-specific relevance of usual blood pressure to vascular mortality. The 
Lancet 2003; 361(9366): 1390-1. 
104. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national 
committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 
7 report. Jama 2003; 289(19): 2560-71. 
105. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the 
management of high blood pressure in adults: report from the panel members appointed to the 
Eighth Joint National Committee (JNC 8). Jama 2014; 311(5): 507-20. 
106. Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus 
standard blood-pressure control. New England Journal of Medicine 2015; 373(22): 2103-16. 
107. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, 
pathophysiology, and management. Jama 2002; 287(19): 2570-81. 
108. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham 
study. Circulation 1979; 59(1): 8-13. 
109. Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes 
mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men 
and women with 20 years of follow-up. Archives of internal medicine 2004; 164(13): 1422-6. 
110. Singer DE, Nathan DM, Anderson KM, et al. Association of HbA1c with prevalent 
cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 
41(2): 202-8. 
111. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent 
vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88(6): 
2510-6. 
112. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in 
diabetes. British journal of pharmacology 2000; 130(5): 963-74. 
51 
 
113. Williams SB, Cusco JA, Roddy M-A, et al. Impaired nitric oxide-mediated 
vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American 
College of Cardiology 1996; 27(3): 567-74. 
114. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes care 
2001; 24(8): 1476-85. 
115. Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term 
hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44(2): 188-95. 
116. Carr ME. Diabetes mellitus: a hypercoagulable state. Journal of diabetes and its 
complications 2001; 15(1): 44-54. 
117. Pearl R. Tobacco smoking and longevity. Science 1938; 87(2253): 216-7. 
118. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular 
diseaseAn update. Journal of the American College of Cardiology 2004; 43(10): 1731-7. 
119. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal 
cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003; 24(11): 
987-1003. 
120. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors 
associated with myocardial infarction in 52 countries (the INTERHEART study): case-control 
study. The Lancet; 364(9438): 937-52. 
121. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, 
physiology, and biochemistry. Circulation 1991; 83(1): 1-12. 
122. Andersen LB, Harro M, Sardinha LB, et al. Physical activity and clustered 
cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). 
The Lancet; 368(9532): 299-304. 
123. Paffenbarger RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk 
in college alumni. American Journal of epidemiology 1978; 108(3): 161-75. 
124. Raitakan OT, Porkka KVK, Taimela S, et al. Effects of Persistent Physical Activity 
and Inactivity on Coronary Risk Factors in Children and Young Adults The Cardiovascular 
Risk in Young Finns Study. American Journal of Epidemiology 1994; 140(3): 195-205. 
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